"But even besides all of the above, a company which has consumed...

"But even besides all of the above, a company which has consumed over a billion dollars of capital over the better part of a decade-and-a-half, and yet still remains underfunded without any signs of self sustaining commercialisation in sight?

That is objectively a fascinating story of corporate evolution, so it is unsurprising that it attracts some attention."

Really? Unfortunately MSB is rather average example of a biotech company development : 10-15 years from founding to product launch (average of 10.5 years from Phase 1 to regulatory approval. And the cost?

"While costs will vary widely depending on many factors including type of drug and disease area, estimates for the average cost of creating a new drug range as high as $2.6 billion USD.

One paper published in JAMA in March 2020 puts the estimate much lower at $985 million USD, though that research relied on publicly available data which was mostly from smaller firms."
https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022